Oncology Institute (NASDAQ:TOI) vs. Zicix (OTCMKTS:ZICXD) Critical Comparison

Oncology Institute (NASDAQ:TOI) and Zicix (OTCMKTS:ZICXD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Oncology Institute and Zicix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1	0	3	1	2.80
Zicix	0	0	0	0	0.00

Oncology Institute presently has a consensus price target of $6.50, indicating a potential upside of 116.67%. Given Oncology Institute’s stronger consensus rating and higher probable upside, research analysts clearly believe Oncology Institute is more favorable than Zicix.

Insider & Institutional Ownership

36.9% of Oncology Institute shares are held by institutional investors. 8.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Oncology Institute and Zicix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-13.21%	-1,527.21%	-35.30%
Zicix	N/A	N/A	N/A

Volatility & Risk

Oncology Institute has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Zicix has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings & Valuation

This table compares Oncology Institute and Zicix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$393.41 million	0.75	-$64.66 million	($0.64)	-4.69
Zicix	N/A	N/A	N/A	($100.14)	-0.03

Zicix has lower revenue, but higher earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Zicix, indicating that it is currently the more affordable of the two stocks.

Summary

Oncology Institute beats Zicix on 8 of the 13 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.